NASDAQ: AVXL

NASDAQ: AVXL

Daniel Klamer, PhD, MS, MBA

Vice President of Business Development and Scientific Strategy

Dr. Daniel Klamer has more than 15 years of experience in neuroscience and the orphan disease space, with acquisition, partnering and R&D experience in Europe and the USA. Prior to Anavex he worked at Retrophin and Neurosearch Sweden. At Neurosearch Sweden, Dr. Klamer led and evaluated multiple discovery-phase neuropharmacological research products with an emphasis on strategic evaluation of preclinical and clinical development.

Dr. Klamer earned his PhD in Pharmacology at The Sahlgrenska Academy at University of Gothenburg, Sweden, his MBA at Fordham Gabelli School of Business, and his Post-Doctoral training at the Department of Psychiatry, Yale University School of Medicine. In addition, Dr. Klamer holds a position as an Associate Professor at the Department of Pharmacology at The Sahlgrenska Academy at the University of Gothenburg.

Discover Other Team Members

You are about to leave our website

By clicking “Continue,” you acknowledge that you are leaving the Anavex Life Sciences website and will be redirected to a third-party website operated by NASDAQ or its affiliates.

Anavex Life Sciences does not own, control, maintain, or endorse the content on third-party websites and is not responsible for their accuracy, completeness, or reliability. Any information available through this link is provided by third parties and does not represent the views, opinions, forecasts, or predictions of Anavex Life Sciences or its management.

The linked content is provided for informational purposes only and does not constitute investment advice or an offer to buy or sell securities. Investors should rely on their own independent judgment and consult professional advisors before making any investment decisions.

Continue
Go Back